Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
Annals of Oncology, 06/08/2012
Alba E et al. – Luminal immunophenotype is not enough to identify patients who do not benefit from neoadjuvant chemotherapy (CT). Luminal patients with low proliferation index could potentially avoid CT.